

# Liver Disease Treatments: The Global Market

<https://marketpublishers.com/r/L69CC66BBA30EN.html>

Date: April 2025

Pages: 164

Price: US\$ 4,650.00 (Single User License)

ID: L69CC66BBA30EN

## Abstracts

### Report Scope:

This report on the global market for liver disease treatments provides qualitative and quantitative data on the current market dynamics. It discusses different liver diseases and their treatment modalities.

Analyses of the most frequently used products, clinical trials, new product approvals, and emerging technologies are also included. The demographics of the major regions—North America, Europe, Asia-Pacific, South America, and the Middle East and Africa—as well as their prospects for growth are summarized. The profiles of leading companies in the market and their strategies are also discussed.

The market for liver disease treatments is broken into hepatitis, non-alcoholic fatty liver disease (NAFLD), hepatocellular carcinoma, autoimmune liver diseases, alcohol-induced liver disease (ALD), chronic liver disease, and others. The growth potential and forecast data are discussed for each disease for the aforementioned regions and many countries.

The report includes global revenue in \$ millions for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030.

### Report Includes :

52 data tables and 63 additional tables

Analyses of the trends in the global markets for liver disease treatments, with revenue data from 2023, estimates for 2024, forecasts for 2025, and projected CAGRs through 2029

Estimates of the size and revenue prospects for the global market, along with a market share analysis by product (drug) type, disease type, route of administration, end user, and region

Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables

Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses

An assessment of the major drugs that can cause liver disease, the market's current situation and future prospects, clinical trials, new developments, and pipeline products

An analysis of the key patent grants and recently published patents

Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes

Analysis of the industry structure, including companies' product offerings, strategic alliances, M&A activity, venture fundings and investment outlook

Company profiles of major players within the industry, including Gilead Sciences Inc., Bristol Myers Squibb Co., AbbVie Inc., and Merck & Co. Inc.

## Contents

### CHAPTER 1 EXECUTIVE SUMMARY

Market Outlook  
Scope of Report  
Market Summary

### CHAPTER 2 MARKET OVERVIEW

Overview  
Classification of Therapies, by Disease and Product  
Hepatitis  
Liver Tumors and Liver Cancer  
Autoimmune Liver Diseases  
Alcohol-induced liver disease  
Chronic Liver Disease  
Non-Alcoholic Fatty Liver Disease  
Analysis of Macroeconomic Factors  
Population Demographics and Aging Population  
Global Economic Growth  
Geopolitical Risks, Trade Wars, and Supply Chain Disruptions  
Public Awareness and Education  
Porter's Five Forces  
Potential for New Entrants (Moderate to Low)  
Bargaining Power of Suppliers (Moderate to High)  
Bargaining Power of Buyers (Moderate to High)  
Threat of Substitute Products or Services (Low to Moderate)  
Industry Competitiveness (High)

### CHAPTER 3 MARKET DYNAMICS

Overview  
Market Drivers  
Increasing Incidence of Liver Diseases  
Consumption of Alcohol and Improper Diet  
Government Initiatives to Provide Vaccines and Grow Awareness  
Market Restraints  
FDA Approvals and Stringent Government Regulations

Side Effects and Risks Associated with Drugs  
Market Opportunities  
Advances in Treatment Options  
Emerging Markets and Access to Treatment

## **CHAPTER 4 REGULATORY LANDSCAPE**

Global Regulatory Agencies  
U.S. Food and Drug Administration  
European Medicines Agency  
Japan's Pharmaceuticals and Medical Devices Agency  
China's National Medical Products Administration  
Considerations in Liver Drug Development

## **CHAPTER 5 EMERGING TRENDS AND PIPELINE ANALYSIS**

Emerging Trends  
Personalized Medicine in Liver Disease  
Advances in Liver Transplantation  
Regenerative Medicine and Stem Cell Therapy  
Immunotherapy for Liver Cancer  
Repairing Liver Disease with mRNA  
Pipeline Analysis  
Patent Analysis  
Findings

## **CHAPTER 6 MARKET SEGMENTATION ANALYSIS**

Segmentation Breakdown  
Market Breakdown, by Disease Type  
Takeaways  
Hepatitis  
Non-Alcoholic Fatty Liver Disease  
Hepatocellular Carcinoma  
Autoimmune Liver Diseases  
Alcohol-induced Liver Disease (ALD)  
Chronic Liver Disease  
Other Liver-Related Diseases  
Geographic Breakdown

Market Breakdown, by Region

Takeaways

North America

Europe

Asia-Pacific

South America

Middle East and Africa

## **CHAPTER 7 COMPETITIVE INTELLIGENCE**

Takeaways

Market Ranking of Leading Companies

Strategic Analysis

Venture Funding and Investments

## **CHAPTER 8 SUSTAINABILITY IN THE LIVER DISEASE TREATMENT INDUSTRY: ESG PERSPECTIVE**

Overview

Environmental Sustainability

Social Responsibility (S)

Governance

ESG Risk Ratings

Concluding Remarks from BCC

## **CHAPTER 9 APPENDIX**

Research Methodology

Sources

Abbreviations

Company Profiles

ABBVIE INC.

ASTRAZENECA

BAYER AG

BIOTEST AG

BRISTOL-MYERS SQUIBB CO.

F. HOFFMANN-LA ROCHE LTD.

GILEAD SCIENCES INC.

GSK PLC.

INTERCEPT PHARMACEUTICALS INC.  
MADRIGAL PHARMACEUTICALS  
MERCK & CO. INC.  
NOVARTIS AG  
SALIX PHARMACEUTICALS  
SANOFI  
TAKEDA PHARMACEUTICAL CO. LTD.  
Emerging Start-ups/Market Disruptors

## 12. LIST OF TABLES

Summary Table : Global Market for Liver Disease Treatments, by Region, Through 2030

Table 1 : Vaccines for Preventing Hepatitis A and B

Table 2 : Drugs Used to Treat Autoimmune Liver Diseases

Table 3 : Porter's Five Forces: Rating Scale

Table 4 : Estimates of the Burden of Chronic Hepatitis B and C, by WHO Region, 2022

Table 5 : Possible Side Effects of Liver Treatment Drugs

Table 6 : FDA Drug Approvals for Liver Treatment, 2022-2024

Table 7 : EMA Drug Approvals for Liver Treatment, 2024 and 2025

Table 8 : Drugs Approved by the PMDA for Liver Treatment, 2022-2024

Table 9 : Pipeline Drugs for Liver Disease Treatment in Phases 3 and 4, 2024

Table 10 : Granted Patents in Liver Drugs, 2023-2025

Table 11 : Global Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 12 : Global Market for Treatments for Hepatitis, by Region, Through 2030

Table 13 : Pipeline Drugs for NAFLD

Table 14 : Global Market for Treating NAFLD, by Region, Through 2030

Table 15 : Countries with Highest Incidence of Liver Cancer, 2022

Table 16 : Global Market for Treating Hepatocellular Carcinoma, by Region, Through 2030

Table 17 : Global Market for Treating Autoimmune Liver Diseases, by Region, Through 2030

Table 18 : Global Market for Treating Alcohol-induced Liver Disease, by Region, Through 2030

Table 19 : Global Market for Treating Chronic Liver Disease, by Region, Through 2030

Table 20 : Global Market for Treating Other Liver Diseases, by Region, Through 2030

Table 21 : Global Market for Liver Disease Treatments, by Region, Through 2030

Table 22 : North American Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 23 : North American Market for Liver Disease Treatments, by Country, Through 2030

Table 24 : U.S. Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 25 : Canadian Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 26 : Liver Transplants from Donors, Per Center in Mexico, in 2023

Table 27 : Mexican Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 28 : European Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 29 : European Market for Liver Disease Treatments, by Country, Through 2030

Table 30 : German Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 31 : Premature Mortality Due to Alcoholic Liver Disease, 2019, 2022, 2023

Table 32 : U.K. Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 33 : French Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 34 : Spanish Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 35 : Italian Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 36 : Rest of European Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 37 : Asia-Pacific Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 38 : Asia-Pacific Market for Liver Disease Treatments, by Country, Through 2030

Table 39 : Chinese Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 40 : Japanese Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 41 : Indian Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 42 : Rest of Asia-Pacific Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 43 : South American Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 44 : South American Market for Liver Disease Treatments, by Country, Through 2030

Table 45 : Brazilian Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 46 : Argentinian Market for Liver Disease Treatments, by Disease Type, Through

2030

Table 47 : Rest of South American Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 48 : MEA Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 49 : MEA Market for Liver Disease Treatments, by Region, Through 2030

Table 50 : Middle East Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 51 : African Market for Liver Disease Treatments, by Disease Type, Through 2030

Table 52 : Leading Companies in the Market for Liver Disease Treatments, 2024

Table 53 : Recent Venture Funding in the Liver Disease Treatment Industry

Table 54 : ESG Risk Rankings for Pharmaceutical Firms in the Liver Disease Market

Table 55 : Report Information Sources

Table 56 : Abbreviations Used in the Report

Table 57 : AbbVie Inc.: Company Snapshot

Table 58 : AbbVie Inc.: Financial Performance, FY 2023 and 2024

Table 59 : AbbVie Inc.: Product Portfolio

Table 60 : AstraZeneca: Company Snapshot

Table 61 : AstraZeneca: Financial Performance, FY 2023 and 2024

Table 62 : AstraZeneca: Product Portfolio

Table 63 : AstraZeneca: News/Key Developments, 2022 and 2023

Table 64 : Bayer AG: Company Snapshot

Table 65 : Bayer AG: Financial Performance, FY 2023 and 2024

Table 66 : Bayer AG: Product Portfolio

Table 67 : Bayer AG: News/Key Developments, 2023 and 2024

Table 68 : Biotest AG: Company Snapshot

Table 69 : Biotest AG: Financial Performance, FY 2023 and 2024

Table 70 : Biotest AG: Product Portfolio

Table 71 : Biotest AG: News/Key Developments, 2023

Table 72 : Bristol-Myers Squibb Co.: Company Snapshot

Table 73 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024

Table 74 : Bristol-Myers Squibb Co.: Product Portfolio

Table 75 : Bristol-Myers Squibb Co.: News/Key Developments, 2025

Table 76 : F. Hoffmann-La Roche Ltd.: Company Snapshot

Table 77 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024

Table 78 : F. Hoffmann-La Roche Ltd.: Product Portfolio

Table 79 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023

Table 80 : Gilead Sciences Inc.: Company Snapshot

Table 81 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024



Table 82 : Gilead Sciences Inc.: Product Portfolio
Table 83 : Gilead Sciences Inc.: News/Key Developments, 2024
Table 84 : GSK plc.: Company Snapshot
Table 85 : GSK plc.: Financial Performance, FY 2023 and 2024
Table 86 : GSK plc.: Product Portfolio
Table 87 : GSK plc.: News/Key Developments, 2024
Table 88 : Intercept Pharmaceuticals Inc.: Company Snapshot
Table 89 : Intercept Pharmaceuticals Inc.: Product Portfolio
Table 90 : Intercept Pharmaceuticals Inc.: News/Key Developments, 2024
Table 91 : Madrigal Pharmaceuticals: Company Snapshot
Table 92 : Madrigal Pharmaceuticals: Financial Performance, FY 2023 and 2024
Table 93 : Madrigal Pharmaceuticals: Product Portfolio
Table 94 : Madrigal Pharmaceuticals: News/Key Developments, 2024
Table 95 : Merck & Co. Inc.: Company Snapshot
Table 96 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 97 : Merck & Co. Inc.: Product Portfolio
Table 98 : Merck & Co. Inc.: News/Key Developments, 2024
Table 99 : Novartis AG: Company Snapshot
Table 100 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 101 : Novartis AG: Product Portfolio
Table 102 : Novartis AG: News/Key Developments, 2022
Table 103 : Salix Pharmaceuticals: Company Snapshot
Table 104 : Salix Pharmaceuticals: Product Portfolio
Table 105 : Salix Pharmaceuticals: News/Key Developments, 2023
Table 106 : Sanofi: Company Snapshot
Table 107 : Sanofi: Financial Performance, FY 2023 and 2024
Table 108 : Sanofi: Product Portfolio
Table 109 : Sanofi: News/Key Developments, 2024
Table 110 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 111 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 112 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 113 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023 and 2024
Table 114 : Emerging Startups

## 12. LIST OF FIGURES

Summary Figure : Shares of Global Market for Liver Disease Treatments, by Region, 2024

Figure 1 : Porter's Five Forces Analysis

Figure 2 : Market Dynamics of Liver Disease Treatments

Figure 3 : Distribution of Death by Liver Diseases in England, by Age Group, 2020

Figure 4 : Clinical Trial Studies of Liver Treatment Drugs, by Trial Phase, 2024

Figure 5 : Patent Analysis of Liver Treatment Drugs, 2022-2025

Figure 6 : Shares of Global Market for Liver Disease Treatments, by Disease Type, 2024

Figure 7 : Shares of Global Market for Hepatitis Treatments, by Region, 2024

Figure 8 : Shares of Global Market for Treating NAFLD, by Region, 2024

Figure 9 : Shares of Global Market for Treating Hepatocellular Carcinoma, by Region, 2024

Figure 10 : Shares of Global Market for Treating Autoimmune Liver Diseases, by Region, 2024

Figure 11 : Shares of Global Market for Treating Alcohol-induced Liver Disease, by Region, 2024

Figure 12 : Shares of Global Market for Treating Chronic Liver Disease, by Region, 2024

Figure 13 : Shares of Global Market for Treating Other Liver Diseases, by Region, 2024

Figure 14 : Shares of Global Market for Liver Disease Treatments, by Region, 2024

Figure 15 : Shares of North American Market for Liver Disease Treatments, by Disease Type, 2024

Figure 16 : Shares of North American Market for Liver Disease Treatments, by Country, 2024

Figure 17 : Shares of U.S. Market for Liver Disease Treatments, by Disease Type, 2024

Figure 18 : Shares of Canadian Market for Liver Diseases Treatments, by Disease Type, 2024

Figure 19 : Shares of Mexican Market for Liver Disease Treatments, by Disease Type, 2024

Figure 20 : Shares of European Market for Liver Disease Treatments, by Disease Type, 2024

Figure 21 : Shares of European Market for Liver Disease Treatments, by Country, 2024

Figure 22 : Deaths Due to Chronic Liver Disease in Germany, 2011-2021

Figure 23 : Shares of German Market for Liver Disease Treatments, by Disease Type, 2024

Figure 24 : Shares of U.K. Market for Liver Disease Treatments, by Disease Type, 2024

Figure 25 : Shares of French Market for Liver Disease Treatments, by Disease Type, 2024

Figure 26 : Shares of Spanish Market for Liver Disease Treatments, by Disease Type, 2024

Figure 27 : Shares of Italian Market for Liver Disease Treatments, by Disease Type,

2024

Figure 28 : Shares of Rest of European Market for Liver Disease Treatments, by Disease Type, 2024

Figure 29 : Shares of Asia-Pacific Market for Liver Disease Treatments, by Disease Type, 2024

Figure 30 : Shares of Asia-Pacific Market for Liver Disease Treatments, by Country, 2024

Figure 31 : Shares of Chinese Market for Liver Disease Treatments, by Disease Type, 2024

Figure 32 : Shares of Japanese Market for Liver Disease Treatments, by Disease Type, 2024

Figure 33 : Shares of Indian Market for Liver Disease Treatments, by Disease Type, 2024

Figure 34 : Shares of Rest of Asia-Pacific Market for Liver Disease Treatments, by Disease Type, 2024

Figure 35 : Shares of South American Market for Liver Disease Treatments, by Disease Type, 2024

Figure 36 : Shares of South American Market for Liver Disease Treatments, by Country, 2023

Figure 37 : Shares of Brazilian Market for Liver Disease Treatments, by Disease Type, 2024

Figure 38 : Shares of Argentinian Market for Liver Disease Treatments, by Disease Type, 2024

Figure 39 : Shares of Rest of South American Market for Liver Disease Treatments, by Disease Type, 2024

Figure 40 : Shares of MEA Market for Liver Disease Treatments, by Disease Type, 2024

Figure 41 : Shares of MEA Market for Liver Disease Treatments, by Region, 2024

Figure 42 : Shares of Middle East Market for Liver Disease Treatments, by Disease Type, 2024

Figure 43 : Shares of African Market for Liver Disease Treatments, by Disease Type, 2024

Figure 44 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024

Figure 45 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024

Figure 46 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024

Figure 47 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024

Figure 48 : Bayer AG: Revenue Shares, by Business Unit, FY 2024

Figure 49 : Bayer AG: Revenue Shares, by Country/Region, FY 2024

Figure 50 : Biotest AG: Revenue Shares, by Business Unit, FY 2024

Figure 51 : Biotest AG: Revenue Shares, by Country/Region, FY 2024

Figure 52 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024

Figure 53 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024

Figure 54 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024

Figure 55 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024

Figure 56 : Gilead Sciences Inc.: Revenue Shares, by Business Unit, FY 2024

Figure 57 : Gilead Sciences Inc.: Revenue Shares, by Country/Region, FY 2024

Figure 58 : GSK plc.: Revenue Shares, by Business Unit, FY 2024

Figure 59 : GSK plc.: Revenue Shares, by Country/Region, FY 2024

Figure 60 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024

Figure 61 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024

Figure 62 : Novartis AG: Revenue Shares, by Business Unit, FY 2024

Figure 63 : Novartis AG: Revenue Shares, by Country/Region, FY 2024

Figure 64 : Sanofi: Revenue Shares, by Business Unit, FY 2024

Figure 65 : Sanofi: Revenue Shares, by Country/Region, FY 2024

Figure 66 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2023

Figure 67 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2023

## I would like to order

Product name: Liver Disease Treatments: The Global Market

Product link: <https://marketpublishers.com/r/L69CC66BBA30EN.html>

Price: US\$ 4,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L69CC66BBA30EN.html>